Harvard Bioscience Q3 revenue beats estimates, net loss narrows

Harvard Bioscience

06/11/2025 12:20

Overview

Harvard Bioscience Q3 revenue of $20.6 mln beats analyst expectations

Net loss for Q3 reduced to $1.2 mln from $4.8 mln last year

Company plans to refinance or repay debt in Q4

Outlook

Company expects Q4 2025 revenues between $22.5 mln and $24.5 mln

Harvard Bioscience anticipates Q4 2025 gross margin of 58% to 60%

Company plans to refinance or repay debt in Q4 2025

Result Drivers

CUSTOMER ENGAGEMENT - Increased customer engagement and order growth contributed to a significant backlog, the highest in nearly two years, per CEO John Duke

FINANCIAL DISCIPLINE - Focus on financial and operational discipline contributed to improved results, according to CEO John Duke

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$20.59 mln
$20 mln (2 Analysts)
Q3 Net Income
-$1.23 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Harvard Bioscience Inc is $2.00, about 70.6% above its November 5 closing price of $0.59

The stock recently traded at 6 times the next 12-month earnings vs. a P/E of 7 three months ago

Press Release: ID:nGNX1HVB80

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)